Reducing mortality from anthrax bioterrorism: Strategies for stockpiling and dispensing medical and pharmaceutical supplies

Biosecurity and Bioterrorism

Volumn 4, Issue 3, 2006, Pages 244-262

  Bravata, Dena M ^a,e   Zaric, Gregory S ^c   Holty, Jon Erik C ^a,b   Brandeau, Margaret L ^d   Wilhelm, Emilee R ^a   McDonald, Kathryn M ^a   Owens, Douglas K ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Stanford University   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BIOLOGICAL WARFARE; DISASTER PLANNING; DISEASE COURSE; HEALTH SERVICES RESEARCH; HUMAN; MONTE CARLO METHOD; MORTALITY; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; UNITED STATES;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; BIOTERRORISM; DISASTER PLANNING; DISEASE PROGRESSION; HEALTH SERVICES RESEARCH; HUMANS; MODELS, ORGANIZATIONAL; MONTE CARLO METHOD; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 33749516130     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2006.4.244     Document Type: Article

References (67)

1. Terriff CM, Tee AM. Citywide pharmaceutical preparation for bioterrorism. Am J Health Syst Pharm 2001;58(3): 233-237.
2. Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis 2001; 32(3):436-445.
3. Koplan J. CDC's strategic plan for bioterrorism preparedness and response. Public Health Rep 2001;116(Suppl 2): 9-16.
4. U.S. Centers for Disease Control and Prevention. Strategic National Stockpile. Atlanta: U.S. Centers for Disease Control and Prevention; April 14, 2005. Available at: http://www.bt.cdc.gov/stockpile/index.asp. Accessed April 6, 2004.
5. U.S. Medicine Institute for Health Studies. Surge Capacity: Is It Time to Move Beyond 'Just-in-Time'? Washington, DC: U.S. Medicine Institute for Health Studies; June 1, 2002. Available at: www.usminstitute.org/jun02surgeagenda.html. Accessed August 13, 2003.
6. Benson B, McKinney P. Selecting & stocking antidotes to biological/chemical agents. Paper presented to: Texas Society of Hospital Pharmacists Annual Meeting; 2003.
7. Case GG, West BM, McHugh CJ. Hospital preparedness for biological and chemical terrorism in central New Jersey. N J Med 2001;98(11):23-33.
8. Bravata DM, McDonald KM, Owens DK, et al. (Agency for Healthcare Research and Quality). Regionalization of Bioterrorism Preparedness and Response. 2004 April. Evidence Report/Technology Assessment Report No. 04-E016-2. Prepared by Stanford-University of California San Francisco Evidence-based Practice Center under Contract No. 290-02-0017.
9. HHS announces $1.1 billion in funding to states for bioterrorism preparedness [press release]. Washington, DC: U.S. Department of Health and Human Services; January 31, 2002. Available at: http://www.hhs.gov/news/press/ 2002 pres/20020131b.html. Accessed February 16, 2004.
10. Hupert N, Cuomo J, Callahan MA, Mushlin AI, Morse S. (Agency for Healthcare Research and Quality). Community-Based Mass Prophylaxis: A Planning Guide for Public Health Preparedness. 2004 August. Prepared by Weill Medical College of Cornell University, Department of Public Health, under Contract No. 290-02-0013-3. AHRQ Pub No. 04-0044.
11. U.S. Centers for Disease Control and Prevention. Cities Readiness Initiative (CRI) Guidance. Atlanta: U.S. Centers for Disease Control and Prevention; July 17, 2006. Available at: http://www.bt.cdc.gov/planning/ coopagreement/#fy06. Accessed July 26, 2006.
12. Zaric GS, Brandeau ML, Bravata DM, Holty J-EC, McDonald KM, Owens DK. Modeling the logistics of response to anthrax bioterrorism. Palo Alto, Calif: Department of Management Science and Engineering, Stanford University; 2006.
13. U.S. Census Bureau. Statistical Abstract of the United States. Report No. 26. Large Metropolitan Statistical Areas-Population: 1990 to 2002. Washington, DC: U.S. Census Bureau; 2003.
14. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A 2003;100(17):10129-10132.
15. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci U S A 2003;100(7): 4346-4351.
16. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM. Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-280.
17. Bell DM, Kozarsky PE, Stephens DS. Conference summary: clinical issues in prophylaxis, diagnosis and treatment of anthrax. Emerg Infect Dis 2002;8(2):222-225.
18. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002;8(10):1124-1132.
19. Rapoport J, Teres D, Zhao Y, Lemeshow S. Length of stay data as a guide to hospital economic performance for ICU patients. Med Care 2003;41(3):386-397.
20. Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 2003;31(1 Suppl):S17-S24.
21. U.S. Department of Health and Human Services. Medicare and Medicaid 2003 Reimbursement Schedules. Washington, DC: Center for Medicare and Medicaid Services; U.S. Department of Health and Human Services; 2003. Available at: http://cms.hhs.gov/. Accessed September 5, 2003.
22. Center for Infectious Disease Research and Policy (CIDRAP) and Infectious Diseases Society of America (IDSA). Clinical Pathway: Anthrax Inhalational Exposure. Minneapolis: Center for Infectious Disease Research and Policy and Infectious Diseases Society of America; 2002. Available at: http://www.cidrap. umn.edu/cidrap/files/17/anthrax-clinical-pathway.pdf. Accessed September 9, 2003.
23. Bravata D, McDonald K, Smith W, et al. Systematic review: surveillance systems for early detection of bioterrorism-related diseases. Ann Intern Med 2004;140(11):910-922.
24. Osterholm MT. How to vaccinate 30,000 people in three days: realities of outbreak management. Public Health Rep 2001;116(Suppl 2):74-78.
25. Krause G, Blackmore C, Wiersma S, Lesneski C, Gauch L, Hopkins RS. Mass vaccination campaign following community outbreak of meningococcal disease. Emerg Infect Dis 2002;8(12):1398-1403.
26. Mass Immunization Campaigns: A "How to" Guide Based on Experience During the February 2000 Capital Health Meningococcal Immunization Campaign. 2000.
27. Hupert N, Mushlin AI, Callahan MA. Modeling the public health response to bioterrorism: using discrete event simulation to design antibiotic distribution centers. Med Decis Making 2002;22(5 Suppl):S17-S25.
28. U.S. Government Accounting Office. GAO Congressional Report: Bioterrorism: preparedness varied across state and local jurisdictions. Washington, DC: U.S. Government Accounting Office; 2003.
29. Wetter DC, Daniel WE, Treser CD. Hospital preparedness for victims of chemical or biological terrorism. Am J Public Health 2001;91(5):710-716.
30. Parizek B. Department of Health Public Health Preparedness Update. Florida Department of Public Health; November 1, 2002. Available at: http://www.foma.org/assets/DOHpreparedness11-1-02.pdf Accessed May 5, 2004.
31. U.S. Centers for Disease Control and Prevention. Receiving, Distributing, and Dispensing the National Pharmaceutical Stockpile: A Guide for Planners. Version 9, Draft. Atlanta: U.S. Centers for Disease Control and Prevention; April 2002.
32. U.S. Centers for Disease Control and Prevention. National Pharmaceutical Stockpile. Atlanta: U.S. Centers for Disease Control and Prevention. Available at: www.bt.cdc.gov/DocumentsApp/NationalStockpile/national_pharmaceutical_ stockpile.pdf. Accessed August 27, 2003.
33. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
34. Owens DK. Interpretation of cost-effectiveness analyses [editorial]. J Gen Intern Med 1998;13:716-717.
35. U.S. Department of the Interior; U.S. Geological Survey. Earthquake Probabilities in the San Francisco Bay Region: 2002-2031. Washington, DC: U.S. Department of the Interior; U.S. Geological Survey; 2003. Open-File Report 03-214.
36. Workshop on Near Earth Objects: Risks, Policies and Actions. Sixth Meeting of the Organisation for Economic Cooperation and Development (OECD) Global Science Forum; Frascati, Italy; 2003.
37. Center for Infectious Disease Research and Policy. BioWatch program aims for nationwide detection of airborne pathogens. CIDRAP News. Minneapolis: Center for Infectious Disease Research & Policy; Academic Health Center, University of Minnesota; March 10, 2003. Available at: http://www.cidrap.umn. edu/cidrap/content/bt/bioprep/news/biowatch.html. Accessed July 26, 2006.
38. Wilson I, Ralston WKJ. Scenario Planning Handbook: Developing Strategies in Uncertain Times. Boston, Mass: South-Western Educational Publishing; 2006.
39. Nickel RH, Mangel M. Weapon acquisition with target uncertainty. Naval Research Logistics 1985;32:567-588.
40. Froggett S, Liu S. System performance modeling in C41SR/weapon system design and development. Naval Engineers J 2001;113:55-63.
41. Brown GG, Clemence RD, Teufert WR, Wood RK. An optimization model for modernizing the Army helicopter fleet. Interfaces 1991;21:39-52.
42. U.S. Centers for Disease Control and Prevention. Anthrax Q & A: Preventive Therapy. Atlanta: U.S. Centers for Disease Control and Prevention; March 25, 2005. Available at: http://www.bt.cdc.gov/agent/anthrax/faq/ preventive.asp. Accessed July 26, 2006.
43. Brook I. The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002;20(5):320-325.
44. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax. JAMA 2002;287(5):579.
45. From the Centers for Disease Control and Prevention. Recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. JAMA 2001;286(21):2663-2664.
46. Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med 2005;142:601-610.
47. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001;2(2):233-247.
48. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002;8(10):1138-1144.
49. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7(6):933-944.
50. Rinnert KJ, Parris T, Zibulewsky J. Local perspectives on bioterrorism: CME, Part 3 of 3. Baylor Univ Med Center Proc 2001;14(3):231-238.
51. Pegues D. UCLA Hospital in a Potential Emergency. Los Angeles: UCLA International Institute; 2002. Available at: http://www.isop.ucla.edu/article. asp?parentid=1917. Accessed September 3, 2003.
52. Hejik K. Pharmacy responds to terrorist attacks. (www.pharmacist.com). Available at: www.pharmacist. com/articles/h_ts_0001.cfm. Accessed September 3, 2003.
53. Cohen ML. Bioterrorism: CDC's Public Health Response. Testimony before the Committee on Governmental Affairs and Subcommittee on International Security, Proliferation and Federal Services, United States Senate. October 30. Available at: www.hhs.gov/asl/testify/t011030.html. Accessed September 3, 2003.
54. Bradsher K. Bayer agrees to charge government a lower price for anthrax medicine. New York Times 2001 October 25.
55. Department of Veterans Affairs. VA Federal Supply Schedule Service Pharmaceuticals: Current Pharmaceutical Products and Pricing. Washington, DC: Department of Veterans Affairs, Office of Acquisition and Materiel Management's National Acquisition Center. Available at: http://www1.va.gov/oamm/acquisitions/ nac/fsss/pharmfss. htm. Accessed September 3, 2003.
56. Office of Inspector General, U.S. Department of Health and Human Services. Cost Containment of Medicaid HIV/AIDS Drug Expenditures. Report No.: OEI-05-99-00611. Washington, DC: U.S. Department of Health and Human Services; July 2001.
57. MarkeTips. Veterans Administration Supply News 2000 January/February.
58. Hupert N, Cuomo J. Weill/Cornell Mass Prophylaxis/Vaccination Model. Available at: http://www.ahcpr.gov/research/biomodel/index.asp. Accessed September 3, 2003.
59. U.S. Office of Personnel Management. 2003 Federal Employee Pay Tables. Washington, DC: U.S. Office of Personnel Management; 2003. Available at: www.opm.gov. Accessed September 5, 2003.
60. U.S. Department of State. International Information Programs. Washington, DC: U.S. Department of State. Available at: http://usinfo.state.gov/topical/ pol/terror/01102416. htm. Accessed September 5, 2003.
61. U.S. Census Bureau. Data Profiles. Washington, DC: U.S. Census Bureau. Available at: http://www.census.gov/acs/www/Products/index.htm. Accessed September 3, 2003.
62. Dartmouth Atlas of Health Care, the Pacific States. Dartmouth: Center for the Evaluative Clinical Sciences, Dartmouth Medical School. Available at: www.dartmouthatlas.org/. Accessed September 3, 2003.
63. SMARTpages. Available at: www.smartpages.com/. Accessed September 3, 2003.
64. Tommy G. Thompson, Secretary, Department of Health and Human Services; Statement on Federal Efforts to Coordinate and Prepare for Bioterrorism: The HHS Role. Committee on Governmental Affairs and Subcommittee on International Security, Proliferation and Federal Services. Washington, DC; 2001.
65. Kevin Yeskey, MD; Director, Bioterrorism Preparedness and Response Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention; Statement on Bioterrorism: CDC's Public Health Response. House Committee on Veterans Affairs, Subcommittee on Health. Washington, DC; 2002.
66. Evans L. Southern California Plans Defenses against Bioterror Attack. Los Angeles: UCLA International Institute; June 5, 2002. Available at: http://www.international.ucla.edu/article.asp?parentid=1917. Accessed September 3, 2003.
67. U.S. Office of Personnel Management. Salary Tables and Related Information. Washington, DC: U.S. Office of Personnel Management; 2004. Available at: http://www.opm.gov/oca/04tables/index.asp. Accessed February 2, 2004.